Menu
Recruiting NCT07126327

Peristeen Light Explorative Clinical Investigation

No phase Interventional Faecal Incontinence Constipation - Functional

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Peristeen Light - trans anal irrigation system.
Who it may be relevant to
Registry conditions: Faecal Incontinence, Constipation - Functional. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Denmark, Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

An Explorative Clinical Investigation to Understand the Clinical Benefits of Peristeen Light

Overview

The goal of this exploratory clinical investigation is to understand the clinical benefits of Peristeen Light in adult patients with faecal incontinence, chronic constipation and/or time-consuming bowel management procedures. The primary objective is to evaluate changes in bowel-function when using Peristeen Light. Participants will use Peristeen Light for 12 weeks test period.

Detailed description

The goal of this exploratory clinical investigation is to understand the clinical benefits of Peristeen Light in adult patients with faecal incontinence, chronic constipation and/or time-consuming bowel management procedures.

The primary endpoint is bowel function measured on a 10 cm Visual Analog Scale (VAS) at Baseline Visit and end of Clinical Investigation visit.

Participants will use Peristeen Light for 12 weeks test period.

Interventions

  • Device Peristeen Light - trans anal irrigation system
    Subjects naive to TAI will use Peristeen Light trans anal irrigation

Primary outcome measures

  • Bowel function measured on a 10 cm Visual Analog Scale (VAS) at Baseline Visit (V1) and End of Clinical Investigation Visit (V7). [Time frame: From enrollment to the end of treatment at week 12.]

Eligibility criteria

Inclusion criteria

  • Has given written informed consent
  • Is at least 18 years old
  • Has full legal capacity
  • Is able (assessed by investigator) and willing to adhere to clinical investigational procedures during clinical investigation-al duration
  • Has access to and is able to use a smartphone
  • Has constipation and/or faecal incontinence based on one or more of the following symptoms during the last 3 month: Straining in more than 25% of defecations, lumpy stools (Bristol Stool Type 1 and 2) in more than 25% of defecations, sensation of incomplete evacuation in more than 25% of defecations, sensation of anorectal obstruction/blockage in more than 25% of defecations, need to use manual maneuvers to facilitate defecation in more than 25% of defecations, fewer than three spontaneous bowel movements per week, loose stools are rarely present without use of laxatives, recurrent uncontrolled passage of faecal material (other words to describe this could be: Soiling, leak-age, passive faecal incontinence of flatus, mucus and/or stool)
  • Is assessed (by investigator) to have a need for low-volume TAI minimum every other day

Exclusion criteria

  • Is participating in any other clinical investigation during this investigation
  • Has previously completed this investigation
  • Is former or current user of transanal irrigation (low- and high volume)
  • Has known hypersensitivity towards the device used in the investigation
  • Is pregnant
  • Has known anal stenosis
  • Has active/recurrent colorectal cancer
  • Has had anastomotic colorectal surgery within the last 3 months
  • Has ischaemic colitis
  • Has active inflammatory bowel disease
  • Has acute diverticulitis or diverticular abscess
  • Has medicine induced constipation (e.g. due to opioids)
  • Has chronic diarrhea
  • Has bowel dysfunction due to neurogenic disorder(s)
  • Is in need of high-volume TAI (as estimated by investigator)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Denmark · 1 center
  • Århus University Hospital — Aarhus
Italy · 1 center
  • Montecatone Rehabillitation Institute S.p.A — Bologna

Identifiers

NCT: NCT07126327 · CP378

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗